摘要
子宫内膜癌是常见的妇科恶性肿瘤之一。早期子宫内膜癌患者经过全面分期手术,必要时辅助放化疗,多预后良好,但晚期及复发性子宫内膜癌患者的预后较差,可采取的治疗方式有限。近年来,子宫内膜癌分子分型和基因检测显示出良好的应用前景,为预测患者预后和制定靶向治疗策略提供了重要信息。此外,针对特定靶点的药物研究在子宫内膜癌中取得一定的成果,靶向治疗可能成为晚期或复发性子宫内膜癌患者首选的治疗方式,缓解其临床症状,改善预后和减轻社会负担。
Endometrial carcinoma is one of the most common gynecological malignancies.The prognosis of patients with early endometrial carcinoma is generally good after comprehensive staging laparotomy and adjuvant radiotherapy and chemotherapy when necessary.However,the prognosis of patients with advanced and recurrent endometrial carcinoma is poor and the cure is limited.In recent years,endometrial carcinoma molecular classification and genetic testing show a good application prospect,for predicting the prognosis of patients and providing important information for targeted therapeutic strategies.In addition,researches on drugs targeting specific targets have achieved certain results in endometrial carcinoma,and targeted therapy may become the preferred treatment for patients with advanced or recurrent endometrial carcinoma,alleviating their clinical symptoms,improving prognosis and alleviating social burden.
作者
赵也恬
韩旭
Zhao Yetian;Han Xu(Department of Reproductive Medicine,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《中国医药》
2022年第6期953-956,共4页
China Medicine
关键词
子宫内膜癌
分子靶向治疗
抗肿瘤联合化疗方案
Endometrial carcinoma
Molecular targeted therapy
Antineoplastic combined chemotherapy protocols